{"ticker": {"uuid": "b4b2b17a-14d0-4a22-bd4b-a377bab4827a", "symbol": "TRAW", "name": "Traws Pharma Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Traws Pharma (TRAW) Registration filing Summary", "summary": "Traws Pharma (TRAW) has filed a registration summary outlining its business model as a clinical-stage biopharmaceutical company focused on antiviral and oncology therapies. The company faces financial challenges, including recurring losses and liquidity concerns, but is seeking t", "url": "https://quartr.com/events/traws-pharma-inc-traw-registration-filing_oSsOcBRW", "source_name": "Quartr", "published_at": "2026-07-18T21:40:34", "published_display": "18 Jul 2026 21:40", "sentiment": "negative", "sentiment_pct": 33, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Traws Pharma (TRAW) grants 97,000 stock options to science chief", "summary": "Traws Pharma, Inc. (TRAW) has granted 97,000 stock options to its Chief Science Officer of Virology, Charles David Pauza. The options, priced at $0.68 per share, are part of a compensation award and will vest 100% on July 9, 2027, with an expiration date of July 9, 2036. This tra", "url": "https://www.stocktitan.net/sec-filings/TRAW/form-4-traws-pharma-inc-insider-trading-activity-9985bfa8b5f5.html", "source_name": "Stock Titan", "published_at": "2026-07-16T17:10:15", "published_display": "16 Jul 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma (TRAW) awards 14,150 stock options to director Cautreels", "summary": "Traws Pharma (TRAW) has granted 14,150 stock options to its director Werner Cautreels. These options, awarded on July 9, 2026, have an exercise price of $0.68 per share, will vest 100% after one year, and are set to expire on July 9, 2036. This transaction was reported on an SEC ", "url": "https://www.stocktitan.net/sec-filings/TRAW/form-4-traws-pharma-inc-insider-trading-activity-6e88bb2ac761.html", "source_name": "Stock Titan", "published_at": "2026-07-16T01:41:38", "published_display": "16 Jul 2026 01:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma (TRAW) grants CFO Parker Nolan 90,000 stock options", "summary": "Traws Pharma (TRAW) has granted its Chief Financial Officer, Parker Charles Nolan, 90,000 stock options with an exercise price of $0.68 per share. These options will vest completely on July 9, 2027, which is the first anniversary of the grant date, and will expire on July 9, 2036", "url": "https://www.stocktitan.net/sec-filings/TRAW/form-4-traws-pharma-inc-insider-trading-activity-b099e17c325c.html", "source_name": "Stock Titan", "published_at": "2026-07-16T00:10:15", "published_display": "16 Jul 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Traws Pharma Inc For: 15 July By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Traws Pharma Inc on July 15th, noting that the company's stock symbol is TRAW and its price increased by 1.47%. The content primarily consists of market data, news headlines, and navigational links, typical of a finan", "url": "https://ng.investing.com/news/stock-market-news/form-4-traws-pharma-inc-for-15-july-93CH-2601701", "source_name": "Investing.com Nigeria", "published_at": "2026-07-15T21:38:00", "published_display": "15 Jul 2026 21:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma (TRAW) awards COO 93,000 stock options at $0.68 strike", "summary": "Traws Pharma (TRAW) has granted its Chief Operating Officer, Nikolay Savchuk, 93,000 stock options at an exercise price of $0.68 per share. These options, which expire on July 9, 2036, will vest completely on the first anniversary of the grant date, July 9, 2026. This transaction", "url": "https://www.stocktitan.net/sec-filings/TRAW/form-4-traws-pharma-inc-insider-trading-activity-e781e79dee00.html", "source_name": "Stock Titan", "published_at": "2026-07-15T20:45:53", "published_display": "15 Jul 2026 20:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma (TRAW) awards 14,150 stock options to director Jack E. Stover", "summary": "Traws Pharma, Inc. (TRAW) has granted 14,150 stock options to its director, Jack E. Stover, on July 9, 2026. The options have an exercise price of $0.68 per share and were awarded as compensation under the company's 2021 Incentive Compensation Plan, vesting 100% after one year an", "url": "https://www.stocktitan.net/sec-filings/TRAW/form-4-traws-pharma-inc-insider-trading-activity-9cccd14bd35f.html", "source_name": "Stock Titan", "published_at": "2026-07-15T02:14:14", "published_display": "15 Jul 2026 02:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stock option grant to Traw Pharma (TRAW) director John Leaman", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQQjRiZjlXTXlNNFh0Vk50bzdnVXZXcUptUktNV1BJVXJrZm94LU0zMWxVVVpnVDg0MG16WGk1dk5UeE5nc0xaamZySVlkQnVwSGhHakRkcjhnaWljSk1RY2taTDFtMzgxQVk3OW9iVzlIOEJFaUVjemg5Sm5nYnM3SmJqcGZKd0N5eUNJdUJ2ektSU1RCbE95Y2ktQnMwTGVFX05MTWxUaENXZEh3Q3lj?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T00:25:38+00:00", "published_display": "15 Jul 2026 00:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma (TRAW) awards 14,150 stock options to company director", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNSjFOemNZTVFaUlZIelpscWtxRkJTb3cydF9WQi1oTENTU3NhcnpkX19raU1mcFduN0NPbE50M3dzdTl6TFZleVJFQ19oUDdWaTRtR2ZFOHRUeUUyaURSNVNEVDF5M21LQzlxS0ljTWZEbWhEOUZtVVZVekpSeVhTUHpsREtLWTNDLTR3SXFyZ2tpU1JPUE93bVlFek1iMG1UUF80eENMcVVPTlcxUldB?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T00:25:38+00:00", "published_display": "15 Jul 2026 00:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Traws Pharma Inc For: 14 July By Investing.com", "summary": "This article from Investing.com is a brief announcement regarding a Form 4 filing for Traws Pharma Inc. on July 14. It indicates the stock symbol TRAW and its performance, currently up 2.92%. The piece appears to be a basic notification that such a financial document has been mad", "url": "https://ng.investing.com/news/stock-market-news/form-4-traws-pharma-inc-for-14-july-93CH-2599758", "source_name": "Investing.com Nigeria", "published_at": "2026-07-15T01:14:14", "published_display": "15 Jul 2026 01:14", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma (TRAW) awards 274,000 stock options to CEO Dukes", "summary": "Traws Pharma, Inc. (TRAW) has granted its CEO, Iain D. Dukes, stock options for 274,000 common shares with an exercise price of $0.68 per share. These options, awarded under the company's 2021 Incentive Compensation Plan, will vest 100% on July 9, 2027, and expire on July 9, 2036", "url": "https://www.stocktitan.net/sec-filings/TRAW/form-4-traws-pharma-inc-insider-trading-activity-163a06258f9a.html", "source_name": "Stock Titan", "published_at": "2026-07-15T00:39:13", "published_display": "15 Jul 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma (TRAW) awards 14,150 stock options to board director", "summary": "Traws Pharma's director, Mary Teresa Shoemaker, was granted 14,150 stock options at an exercise price of $0.68 per share on July 9, 2026. These options, granted under the 2021 Incentive Compensation Plan, will vest 100% on their first anniversary and expire on July 9, 2036. This ", "url": "https://www.stocktitan.net/sec-filings/TRAW/form-4-traws-pharma-inc-insider-trading-activity-28ef4c1ec931.html", "source_name": "Stock Titan", "published_at": "2026-07-15T00:14:14", "published_display": "15 Jul 2026 00:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma (TRAW) awards CMO 84,000 stock options at $0.68", "summary": "Traws Pharma, Inc. (TRAW) granted its Chief Medical Officer, Robert Redfield, 84,000 stock options with an exercise price of $0.68 per share. The options were awarded under the company\u2019s 2021 Incentive Compensation Plan, have a transaction price of $0.00, and fully vest on the fi", "url": "https://www.stocktitan.net/sec-filings/TRAW/form-4-traws-pharma-inc-insider-trading-activity-70aad95ce93a.html", "source_name": "Stock Titan", "published_at": "2026-07-15T00:14:14", "published_display": "15 Jul 2026 00:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Traws Pharma Announces New At-The-Market Offering Program", "summary": "Traws Pharma announced a new At-The-Market Offering Agreement with Citizens JMP Securities, LLC, allowing them to sell up to $50 million of common stock. This program provides the company with flexible capital access to support ongoing operations and development activities. Despi", "url": "https://www.theglobeandmail.com/investing/markets/stocks/TRAW/pressreleases/3240480/traws-pharma-announces-new-at-the-market-offering-program/", "source_name": "The Globe and Mail", "published_at": "2026-07-12T11:14:14", "published_display": "12 Jul 2026 11:14", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 424B5 Traws Pharma Inc For: 10 July By Investing.com", "summary": "Investing.com published a Form 424B5 filing for Traws Pharma Inc on July 10th. The article briefly mentions Traws Pharma Inc (TRAW) with a reported gain of 12.59%. It provides no further details on the filing or the company's financials but is part of a larger financial news port", "url": "https://za.investing.com/news/stock-market-news/form-424b5-traws-pharma-inc-for-10-july-93CH-4364842", "source_name": "Investing.com South Africa", "published_at": "2026-07-10T22:08:43", "published_display": "10 Jul 2026 22:08", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma (NASDAQ: TRAW) details $5,575,709 baby shelf ATM stock capacity", "summary": "Traws Pharma (NASDAQ: TRAW) announced details of an at-the-market (ATM) equity offering program through an 8-K filing. The company can sell up to $5,575,709 in common stock under a new prospectus supplement, which reflects its current \"baby shelf\" limitation, through Citizens JMP", "url": "https://www.stocktitan.net/sec-filings/TRAW/8-k-traws-pharma-inc-reports-material-event-27aeea87f139.html", "source_name": "Stock Titan", "published_at": "2026-07-10T20:09:03", "published_display": "10 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma, Inc. SEC Filing", "summary": "This article reports on Traws Pharma, Inc.'s SEC filing, specifically a Notice of Effectiveness for an S-3 form, which became effective on July 9, 2026. The filing indicates a \"Neutral\" impact and sentiment. The company, trading under NASDAQ: TRAW, has a market cap of $10.28 mill", "url": "https://www.stocktitan.net/sec-filings/TRAW/effect-traws-pharma-inc-sec-filing-3cbe7c902471.html", "source_name": "Stock Titan", "published_at": "2026-07-10T10:09:04", "published_display": "10 Jul 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma, Inc. SEC Filing (Jul 10, 2026)", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQdlhoR1I3bVNCa1FTbGpKYkNabUJGaG1RRWQ2YjV2YjRndldKb0V5bURUV1c3YkEwWi1yOVUzVHlVRE9DaFFMUUY4UzdjYllNNVRadDE4dU9qNDRxZ3Ftd3QzYkdObVRGR0dvWWNudUFYZ1dtNW1IbFpPdjY5elV2UERKS0N0U2IyYmt5Q2trdE1ZR1pnZXZFZWZaX3I?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-10T07:00:00+00:00", "published_display": "10 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma, Inc. Files 8-K: Amendment to 2021 Incentive Compensation Plan and Company Details Disclosed", "summary": "Traws Pharma, Inc. (NASDAQ: TRAW) announced the results of its 2026 Annual Meeting of Stockholders, where shareholders approved an amendment to increase the common stock available for its 2021 Incentive Compensation Plan by 2,000,000 shares and ratified KPMG LLP as the independen", "url": "https://www.minichart.com.sg/2026/07/10/traws-pharma-inc-files-8-k-amendment-to-2021-incentive-compensation-plan-and-company-details-disclosed/", "source_name": "Minichart", "published_at": "2026-07-10T01:40:51", "published_display": "10 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma (NASDAQ: TRAW) shareholders approve equity plan expansion and warrant share issuances", "summary": "Traws Pharma shareholders approved the expansion of its 2021 Incentive Compensation Plan by 2,000,000 shares and authorized the issuance of common shares upon the exercise of Series B and Series C warrants from an April 2026 Securities Purchase Agreement. The annual meeting also ", "url": "https://www.stocktitan.net/sec-filings/TRAW/8-k-traws-pharma-inc-reports-material-event-2fb212e0dffd.html", "source_name": "Stock Titan", "published_at": "2026-07-09T19:50:11", "published_display": "09 Jul 2026 19:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma (TRAW) AGM 2026 Summary", "summary": "This article summarizes the Traws Pharma (TRAW) 2026 Annual General Meeting (AGM) held virtually on July 8, 2026. Key items included the election of seven directors, approval of an amendment to the 2021 Incentive Compensation Plan, ratification of KPMG LLP as auditor, and authori", "url": "https://quartr.com/events/traws-pharma-inc-traw-agm-2026_oSsOcBwU", "source_name": "Quartr", "published_at": "2026-07-08T19:09:54", "published_display": "08 Jul 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TRAW - Traws Pharma Inc Options", "summary": "This article provides a detailed financial overview of Traws Pharma Inc (TRAW) options. It includes various real-time financial metrics such as market capitalization, income, sales, insider and institutional ownership, profitability ratios, and stock performance data across diffe", "url": "https://finviz.com/stock?t=TRAW&ty=oc&p=m", "source_name": "Finviz", "published_at": "2026-07-02T20:10:14", "published_display": "02 Jul 2026 20:10", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma files prospectus for $139.2M mixed shelf offering", "summary": "Traws Pharma has filed a prospectus for a mixed shelf offering of up to $139.2 million, allowing it to sell various securities including common stock, preferred stock, debt securities, warrants, and units. The specifics of each offering will be detailed in a prospectus supplement", "url": "https://scanx.trade/stock-market-news/ipo/traws-pharma-files-prospectus-for-139-2m-mixed-shelf-offering/44488747", "source_name": "scanx.trade", "published_at": "2026-07-01T22:10:06", "published_display": "01 Jul 2026 22:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma (TRAW) renews shelf for $139.2M unsold securities", "summary": "Traws Pharma, Inc. (TRAW) has filed a Form S-3 registration statement to renew its shelf for unsold securities, totaling up to $139.2 million. This filing replaces a prior registration statement and allows the company to offer various securities, including common stock, preferred", "url": "https://www.stocktitan.net/sec-filings/TRAW/s-3-traws-pharma-inc-shelf-registration-statement-38f450fefd8f.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:10:06", "published_display": "01 Jul 2026 20:10", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Traws Pharma, Inc. \u2013 NASDAQ:TRAW", "summary": "This article displays the \"Price to book forward\" financial metric for Traws Pharma, Inc. (NASDAQ: TRAW) on TradingView. It presents a value and change percentage for a specified period, noting that the data is made and presented by humans.", "url": "https://www.tradingview.com/symbols/NASDAQ-TRAW/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T05:11:42", "published_display": "29 Jun 2026 05:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Traws Pharma, Inc. \u2013 NASDAQ:TRAW", "summary": "The article focuses on the \"Price to sales forward\" financial metric for Traws Pharma, Inc. (NASDAQ: TRAW), providing a snapshot of its current value and historical changes. It appears to be a financial data snippet from a larger platform rather than a detailed analysis. The cont", "url": "https://www.tradingview.com/symbols/NASDAQ-TRAW/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T23:41:27", "published_display": "28 Jun 2026 23:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TRAW Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Traws Pharma, Inc. (TRAW) stock, based on analyst opinions. It includes current stock performance, historical highs and lows, volatility metrics, market capitalization, and upcoming earnings report dates. The article also cove", "url": "https://www.tradingview.com/symbols/NASDAQ-TRAW/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T05:39:38", "published_display": "27 Jun 2026 05:39", "sentiment": "negative", "sentiment_pct": 40, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program", "summary": "Traws Pharma announced it is developing an updated toxicology data package for its influenza prophylaxis program, tivoxavir marboxil (TXM), in response to requirements from the UK's MHRA. This resubmission, expected in Q3 2026, aims to enable a Phase 2a human influenza Challenge ", "url": "https://www.globenewswire.com/news-release/2026/06/22/3315171/0/en/traws-pharma-provides-updated-guidance-on-influenza-prophylaxis-program.html", "source_name": "GlobeNewswire", "published_at": "2026-06-26T19:40:40", "published_display": "26 Jun 2026 19:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma, Inc. Actuals & Estimates (NASDAQ:TRAW)", "summary": "This article provides an overview of Traws Pharma, Inc. (NASDAQ:TRAW) financials and analyst estimates. Key information includes the current stock price, historical performance, analyst price targets, upcoming earnings dates, and financial metrics such as net income and EBITDA. T", "url": "https://www.tradingview.com/symbols/NASDAQ-TRAW/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T13:39:15", "published_display": "26 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "0T20 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a detailed forecast and financial overview for Traws Pharma, Inc. (0T20) on the Frankfurt Stock Exchange, based on analyst ratings and historical data. It includes information on price targets, past earnings, revenue, EBITDA, and key dates such as the next e", "url": "https://www.tradingview.com/symbols/FWB-0T20/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T23:39:15", "published_display": "25 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma Says Updated Toxicology Data Being Developed on Influenza Prophylaxis Program", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/traws-pharma-says-updated-toxicology-122355728.html", "source_name": "MT Newswires", "published_at": "2026-06-22T12:23:55+00:00", "published_display": "22 Jun 2026 12:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma Delays Phase 2 Influenza Study After UK Regulatory Review; Shares Down Pre-Bell", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/traws-pharma-delays-phase-2-104229416.html", "source_name": "MT Newswires", "published_at": "2026-06-15T10:42:29+00:00", "published_display": "15 Jun 2026 10:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma Shares Slide After UK Regulator Postpones Influenza Study", "summary": "", "url": "https://finance.yahoo.com/m/b775bfc6-294e-3246-9e8a-ee7892d2ef9b/traws-pharma-shares-slide.html", "source_name": "InvestorsHub", "published_at": "2026-06-15T10:26:33+00:00", "published_display": "15 Jun 2026 10:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma Provides Regulatory Update on Influenza Program", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/traws-pharma-provides-regulatory-influenza-213000779.html", "source_name": "GlobeNewswire", "published_at": "2026-06-12T21:30:00+00:00", "published_display": "12 Jun 2026 21:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regulator setback stalls Traws Pharma bird flu drug test in humans", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQV0F4OXZ6SWZKV29FOFRCb3VJLVgwN29lc3Q2QXVMNXduRFA2Nk5WOXU3TVVaaXVBTm13M3Qta0loTzNMVWtUcnNOTnNzN0YxN2lIdG9PcDFPLW01XzVSbFVxUXoyTE16dXRsMWh4aVZFbEhja1h4NW50LVBxbVA2RkszSk9jRFFIWllCMFpwT3RaQ2RWazNqRVhob25CcjVTeUZza3VlLUx5dzA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/traws-pharma-announces-antiviral-program-124500454.html", "source_name": "GlobeNewswire", "published_at": "2026-05-27T12:45:00+00:00", "published_display": "27 May 2026 12:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/traws-pharma-provides-business-highlights-110000040.html", "source_name": "GlobeNewswire", "published_at": "2026-05-15T11:00:00+00:00", "published_display": "15 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "TRAW Stock Price and Chart \u2014 NASDAQ:TRAW", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE81NXdVSkRpeTdhd0pkZkZxa2xQa2MxN1JBMWN2X1I2a0xGa0xjbHZCajdDdXRVbUx3MHcwbVVBTmFyR2w5SjlOUFA5Mk8zbnphVnFLT3RqNFkxRGNf?oc=5", "source_name": "TradingView", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma Advances Development of Clinical Candidates for Hantavirus Treatment", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOeVVCMHdYSzZ0Vm5RbC0zSXNwckJ4QUJ5b1ZmQ0xmMy0ybmVHeGRNakNwSFE1T1ZzS2tsWXBtMHdZU2NpeUhvRWoxM05XWWtGVnZlVHNPQ0psU0N0RVJJUE82aHVWcmhNWjFFcE1xMEk0ckZtWmJiQk9wb0E3bFNyeEIwem9oeWNPNnlMdnp3M2RDM2ZrejRQU3hDRkdSeFh3cDVCa1NjTkFlTlFNWGd2OXlQRjE?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "No approved hantavirus treatment; Traws plans drug push", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQSGZyUnM5ZWI3YVFYNk1zOE1NdzBnRGVvNnY2ZTY1SUxtNjhWUDR3VlFNM0RRa1J3MEw2ZU5aNUJOdmVHbzN1eUV3V1g4QlJxa3F1SXNfaXZOazl4d3BIT3VYSWNXWGpkbk9LRDlHRndVZ2s3OGpRX2pTSENWc3I4TzRsRDZmTlUtcUxLazNheHV1Yk9tX3JtdHk2Z3VmTTNiMDg3OW5QMldJekE0Nm4yTFI4cVlpZHc?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma Stock (TRAW) Opinions on Insider Purchase", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPOW1UbXc4N2s2YTlmUXUzckNxRjhkbnpCWXVhWkIyanFGYXFNYlNjWkQ4V0dZZi1fMmI3TUpKTjlnQTY2b0FOYTNEbm9FXzJ6YUN1SnhXdVhHUEhGVTJmMEkxUjdUVS01VE5lU0hvTTNSWWRVRWpQSnBRcFR6Vnd4VTdObERSekotanZDTGFzTXJ3b0x0cHc?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Traws Pharma stock tumbles after FDA places tivoxavir marboxil on clinical hold", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxNeGhDaHlkNjY0ckZQbGd3ZktGWTIzSGxFUVRTanI4YjFiT016dFRGSHVQSUFua2R3UlJUXzhmMmZuTU1aTmZPdmNMS0NONFdZdzJMcHNkdTNIWjRIQWxSamRvMnJYZHBoSDlLY3ZldW1GRDdSRDM1ZUJXejdVamJMZXhleHlVbVF2aDE3cUFqdXVxYzFqMnZxcnBjVVJmeU1RR1BXeUtsb3hWZVhQTnFtamh0X1BIVGlibk1wVEFMc0NNckZYMDFMbnpiazhTVi1tNkhyTEI2bWE?oc=5", "source_name": "Investing.com", "published_at": "2026-02-19T08:00:00+00:00", "published_display": "19 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma Stock Hits 6-Month Highs On Bird Flu Treatment Breakthrough, Retail Interest Soars", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOQ0dtSzJrNEt0ckR0X2toOERNTnUxNmV4LXlvaWRieC1kM2ZUWlE0Y2lodGNzYkpzekhZODBCOHd2UExMWjFEbzFOMkVlWkFMcmpucGR0TkExblJzSGRTclJTUVJtQ0llZEhOenMtbFNQR3hVbTZuLTdGc0tqU2ZkR0F1OEF0aFctdWZsai1RVllaVS1uZWZTemc1N0swN0VaWGpJSnZEaTRxeGp5cW1sMjlR?oc=5", "source_name": "Stocktwits", "published_at": "2024-12-23T17:12:12+00:00", "published_display": "23 Dec 2024 17:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma (TRAW) Stock News & Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTE5TMDB0ZVpnMnBJQXNpd1lwYzRzQUJvbTY5OVR1WWpZOUd2UjMyTUFCSUpqXzdLclJNYlhZTTVid01pc29kbHc3OFJBa0VRdw?oc=5", "source_name": "Stock Titan", "published_at": "2024-05-07T19:03:12+00:00", "published_display": "07 May 2024 19:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Traws Pharma (TRAW) Registration filing Summary", "summary": "Traws Pharma (TRAW) has filed a registration summary outlining its business model as a clinical-stage biopharmaceutical company focused on antiviral and oncology therapies. The company faces financial challenges, including recurring losses and liquidity concerns, but is seeking t", "url": "https://quartr.com/events/traws-pharma-inc-traw-registration-filing_oSsOcBRW", "source_name": "Quartr", "published_at": "2026-07-18T21:40:34", "published_display": "18 Jul 2026 21:40", "sentiment": "negative", "sentiment_pct": 33, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma (TRAW) grants 97,000 stock options to science chief", "summary": "Traws Pharma, Inc. (TRAW) has granted 97,000 stock options to its Chief Science Officer of Virology, Charles David Pauza. The options, priced at $0.68 per share, are part of a compensation award and will vest 100% on July 9, 2027, with an expiration date of July 9, 2036. This tra", "url": "https://www.stocktitan.net/sec-filings/TRAW/form-4-traws-pharma-inc-insider-trading-activity-9985bfa8b5f5.html", "source_name": "Stock Titan", "published_at": "2026-07-16T17:10:15", "published_display": "16 Jul 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma (TRAW) awards 14,150 stock options to director Cautreels", "summary": "Traws Pharma (TRAW) has granted 14,150 stock options to its director Werner Cautreels. These options, awarded on July 9, 2026, have an exercise price of $0.68 per share, will vest 100% after one year, and are set to expire on July 9, 2036. This transaction was reported on an SEC ", "url": "https://www.stocktitan.net/sec-filings/TRAW/form-4-traws-pharma-inc-insider-trading-activity-6e88bb2ac761.html", "source_name": "Stock Titan", "published_at": "2026-07-16T01:41:38", "published_display": "16 Jul 2026 01:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma (TRAW) grants CFO Parker Nolan 90,000 stock options", "summary": "Traws Pharma (TRAW) has granted its Chief Financial Officer, Parker Charles Nolan, 90,000 stock options with an exercise price of $0.68 per share. These options will vest completely on July 9, 2027, which is the first anniversary of the grant date, and will expire on July 9, 2036", "url": "https://www.stocktitan.net/sec-filings/TRAW/form-4-traws-pharma-inc-insider-trading-activity-b099e17c325c.html", "source_name": "Stock Titan", "published_at": "2026-07-16T00:10:15", "published_display": "16 Jul 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Traws Pharma Inc For: 15 July By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Traws Pharma Inc on July 15th, noting that the company's stock symbol is TRAW and its price increased by 1.47%. The content primarily consists of market data, news headlines, and navigational links, typical of a finan", "url": "https://ng.investing.com/news/stock-market-news/form-4-traws-pharma-inc-for-15-july-93CH-2601701", "source_name": "Investing.com Nigeria", "published_at": "2026-07-15T21:38:00", "published_display": "15 Jul 2026 21:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma (TRAW) awards COO 93,000 stock options at $0.68 strike", "summary": "Traws Pharma (TRAW) has granted its Chief Operating Officer, Nikolay Savchuk, 93,000 stock options at an exercise price of $0.68 per share. These options, which expire on July 9, 2036, will vest completely on the first anniversary of the grant date, July 9, 2026. This transaction", "url": "https://www.stocktitan.net/sec-filings/TRAW/form-4-traws-pharma-inc-insider-trading-activity-e781e79dee00.html", "source_name": "Stock Titan", "published_at": "2026-07-15T20:45:53", "published_display": "15 Jul 2026 20:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma (TRAW) awards 14,150 stock options to director Jack E. Stover", "summary": "Traws Pharma, Inc. (TRAW) has granted 14,150 stock options to its director, Jack E. Stover, on July 9, 2026. The options have an exercise price of $0.68 per share and were awarded as compensation under the company's 2021 Incentive Compensation Plan, vesting 100% after one year an", "url": "https://www.stocktitan.net/sec-filings/TRAW/form-4-traws-pharma-inc-insider-trading-activity-9cccd14bd35f.html", "source_name": "Stock Titan", "published_at": "2026-07-15T02:14:14", "published_display": "15 Jul 2026 02:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stock option grant to Traw Pharma (TRAW) director John Leaman", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQQjRiZjlXTXlNNFh0Vk50bzdnVXZXcUptUktNV1BJVXJrZm94LU0zMWxVVVpnVDg0MG16WGk1dk5UeE5nc0xaamZySVlkQnVwSGhHakRkcjhnaWljSk1RY2taTDFtMzgxQVk3OW9iVzlIOEJFaUVjemg5Sm5nYnM3SmJqcGZKd0N5eUNJdUJ2ektSU1RCbE95Y2ktQnMwTGVFX05MTWxUaENXZEh3Q3lj?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T00:25:38+00:00", "published_display": "15 Jul 2026 00:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma (TRAW) awards 14,150 stock options to company director", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNSjFOemNZTVFaUlZIelpscWtxRkJTb3cydF9WQi1oTENTU3NhcnpkX19raU1mcFduN0NPbE50M3dzdTl6TFZleVJFQ19oUDdWaTRtR2ZFOHRUeUUyaURSNVNEVDF5M21LQzlxS0ljTWZEbWhEOUZtVVZVekpSeVhTUHpsREtLWTNDLTR3SXFyZ2tpU1JPUE93bVlFek1iMG1UUF80eENMcVVPTlcxUldB?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T00:25:38+00:00", "published_display": "15 Jul 2026 00:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Traws Pharma Inc For: 14 July By Investing.com", "summary": "This article from Investing.com is a brief announcement regarding a Form 4 filing for Traws Pharma Inc. on July 14. It indicates the stock symbol TRAW and its performance, currently up 2.92%. The piece appears to be a basic notification that such a financial document has been mad", "url": "https://ng.investing.com/news/stock-market-news/form-4-traws-pharma-inc-for-14-july-93CH-2599758", "source_name": "Investing.com Nigeria", "published_at": "2026-07-15T01:14:14", "published_display": "15 Jul 2026 01:14", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma (TRAW) awards 274,000 stock options to CEO Dukes", "summary": "Traws Pharma, Inc. (TRAW) has granted its CEO, Iain D. Dukes, stock options for 274,000 common shares with an exercise price of $0.68 per share. These options, awarded under the company's 2021 Incentive Compensation Plan, will vest 100% on July 9, 2027, and expire on July 9, 2036", "url": "https://www.stocktitan.net/sec-filings/TRAW/form-4-traws-pharma-inc-insider-trading-activity-163a06258f9a.html", "source_name": "Stock Titan", "published_at": "2026-07-15T00:39:13", "published_display": "15 Jul 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma (TRAW) awards 14,150 stock options to board director", "summary": "Traws Pharma's director, Mary Teresa Shoemaker, was granted 14,150 stock options at an exercise price of $0.68 per share on July 9, 2026. These options, granted under the 2021 Incentive Compensation Plan, will vest 100% on their first anniversary and expire on July 9, 2036. This ", "url": "https://www.stocktitan.net/sec-filings/TRAW/form-4-traws-pharma-inc-insider-trading-activity-28ef4c1ec931.html", "source_name": "Stock Titan", "published_at": "2026-07-15T00:14:14", "published_display": "15 Jul 2026 00:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma (TRAW) awards CMO 84,000 stock options at $0.68", "summary": "Traws Pharma, Inc. (TRAW) granted its Chief Medical Officer, Robert Redfield, 84,000 stock options with an exercise price of $0.68 per share. The options were awarded under the company\u2019s 2021 Incentive Compensation Plan, have a transaction price of $0.00, and fully vest on the fi", "url": "https://www.stocktitan.net/sec-filings/TRAW/form-4-traws-pharma-inc-insider-trading-activity-70aad95ce93a.html", "source_name": "Stock Titan", "published_at": "2026-07-15T00:14:14", "published_display": "15 Jul 2026 00:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma Announces New At-The-Market Offering Program", "summary": "Traws Pharma announced a new At-The-Market Offering Agreement with Citizens JMP Securities, LLC, allowing them to sell up to $50 million of common stock. This program provides the company with flexible capital access to support ongoing operations and development activities. Despi", "url": "https://www.theglobeandmail.com/investing/markets/stocks/TRAW/pressreleases/3240480/traws-pharma-announces-new-at-the-market-offering-program/", "source_name": "The Globe and Mail", "published_at": "2026-07-12T11:14:14", "published_display": "12 Jul 2026 11:14", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 424B5 Traws Pharma Inc For: 10 July By Investing.com", "summary": "Investing.com published a Form 424B5 filing for Traws Pharma Inc on July 10th. The article briefly mentions Traws Pharma Inc (TRAW) with a reported gain of 12.59%. It provides no further details on the filing or the company's financials but is part of a larger financial news port", "url": "https://za.investing.com/news/stock-market-news/form-424b5-traws-pharma-inc-for-10-july-93CH-4364842", "source_name": "Investing.com South Africa", "published_at": "2026-07-10T22:08:43", "published_display": "10 Jul 2026 22:08", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma (NASDAQ: TRAW) details $5,575,709 baby shelf ATM stock capacity", "summary": "Traws Pharma (NASDAQ: TRAW) announced details of an at-the-market (ATM) equity offering program through an 8-K filing. The company can sell up to $5,575,709 in common stock under a new prospectus supplement, which reflects its current \"baby shelf\" limitation, through Citizens JMP", "url": "https://www.stocktitan.net/sec-filings/TRAW/8-k-traws-pharma-inc-reports-material-event-27aeea87f139.html", "source_name": "Stock Titan", "published_at": "2026-07-10T20:09:03", "published_display": "10 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma, Inc. SEC Filing", "summary": "This article reports on Traws Pharma, Inc.'s SEC filing, specifically a Notice of Effectiveness for an S-3 form, which became effective on July 9, 2026. The filing indicates a \"Neutral\" impact and sentiment. The company, trading under NASDAQ: TRAW, has a market cap of $10.28 mill", "url": "https://www.stocktitan.net/sec-filings/TRAW/effect-traws-pharma-inc-sec-filing-3cbe7c902471.html", "source_name": "Stock Titan", "published_at": "2026-07-10T10:09:04", "published_display": "10 Jul 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma, Inc. SEC Filing (Jul 10, 2026)", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQdlhoR1I3bVNCa1FTbGpKYkNabUJGaG1RRWQ2YjV2YjRndldKb0V5bURUV1c3YkEwWi1yOVUzVHlVRE9DaFFMUUY4UzdjYllNNVRadDE4dU9qNDRxZ3Ftd3QzYkdObVRGR0dvWWNudUFYZ1dtNW1IbFpPdjY5elV2UERKS0N0U2IyYmt5Q2trdE1ZR1pnZXZFZWZaX3I?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-10T07:00:00+00:00", "published_display": "10 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma, Inc. Files 8-K: Amendment to 2021 Incentive Compensation Plan and Company Details Disclosed", "summary": "Traws Pharma, Inc. (NASDAQ: TRAW) announced the results of its 2026 Annual Meeting of Stockholders, where shareholders approved an amendment to increase the common stock available for its 2021 Incentive Compensation Plan by 2,000,000 shares and ratified KPMG LLP as the independen", "url": "https://www.minichart.com.sg/2026/07/10/traws-pharma-inc-files-8-k-amendment-to-2021-incentive-compensation-plan-and-company-details-disclosed/", "source_name": "Minichart", "published_at": "2026-07-10T01:40:51", "published_display": "10 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma (NASDAQ: TRAW) shareholders approve equity plan expansion and warrant share issuances", "summary": "Traws Pharma shareholders approved the expansion of its 2021 Incentive Compensation Plan by 2,000,000 shares and authorized the issuance of common shares upon the exercise of Series B and Series C warrants from an April 2026 Securities Purchase Agreement. The annual meeting also ", "url": "https://www.stocktitan.net/sec-filings/TRAW/8-k-traws-pharma-inc-reports-material-event-2fb212e0dffd.html", "source_name": "Stock Titan", "published_at": "2026-07-09T19:50:11", "published_display": "09 Jul 2026 19:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma (TRAW) AGM 2026 Summary", "summary": "This article summarizes the Traws Pharma (TRAW) 2026 Annual General Meeting (AGM) held virtually on July 8, 2026. Key items included the election of seven directors, approval of an amendment to the 2021 Incentive Compensation Plan, ratification of KPMG LLP as auditor, and authori", "url": "https://quartr.com/events/traws-pharma-inc-traw-agm-2026_oSsOcBwU", "source_name": "Quartr", "published_at": "2026-07-08T19:09:54", "published_display": "08 Jul 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TRAW - Traws Pharma Inc Options", "summary": "This article provides a detailed financial overview of Traws Pharma Inc (TRAW) options. It includes various real-time financial metrics such as market capitalization, income, sales, insider and institutional ownership, profitability ratios, and stock performance data across diffe", "url": "https://finviz.com/stock?t=TRAW&ty=oc&p=m", "source_name": "Finviz", "published_at": "2026-07-02T20:10:14", "published_display": "02 Jul 2026 20:10", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma files prospectus for $139.2M mixed shelf offering", "summary": "Traws Pharma has filed a prospectus for a mixed shelf offering of up to $139.2 million, allowing it to sell various securities including common stock, preferred stock, debt securities, warrants, and units. The specifics of each offering will be detailed in a prospectus supplement", "url": "https://scanx.trade/stock-market-news/ipo/traws-pharma-files-prospectus-for-139-2m-mixed-shelf-offering/44488747", "source_name": "scanx.trade", "published_at": "2026-07-01T22:10:06", "published_display": "01 Jul 2026 22:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma (TRAW) renews shelf for $139.2M unsold securities", "summary": "Traws Pharma, Inc. (TRAW) has filed a Form S-3 registration statement to renew its shelf for unsold securities, totaling up to $139.2 million. This filing replaces a prior registration statement and allows the company to offer various securities, including common stock, preferred", "url": "https://www.stocktitan.net/sec-filings/TRAW/s-3-traws-pharma-inc-shelf-registration-statement-38f450fefd8f.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:10:06", "published_display": "01 Jul 2026 20:10", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Traws Pharma, Inc. \u2013 NASDAQ:TRAW", "summary": "This article displays the \"Price to book forward\" financial metric for Traws Pharma, Inc. (NASDAQ: TRAW) on TradingView. It presents a value and change percentage for a specified period, noting that the data is made and presented by humans.", "url": "https://www.tradingview.com/symbols/NASDAQ-TRAW/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T05:11:42", "published_display": "29 Jun 2026 05:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Traws Pharma, Inc. \u2013 NASDAQ:TRAW", "summary": "The article focuses on the \"Price to sales forward\" financial metric for Traws Pharma, Inc. (NASDAQ: TRAW), providing a snapshot of its current value and historical changes. It appears to be a financial data snippet from a larger platform rather than a detailed analysis. The cont", "url": "https://www.tradingview.com/symbols/NASDAQ-TRAW/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T23:41:27", "published_display": "28 Jun 2026 23:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TRAW Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Traws Pharma, Inc. (TRAW) stock, based on analyst opinions. It includes current stock performance, historical highs and lows, volatility metrics, market capitalization, and upcoming earnings report dates. The article also cove", "url": "https://www.tradingview.com/symbols/NASDAQ-TRAW/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T05:39:38", "published_display": "27 Jun 2026 05:39", "sentiment": "negative", "sentiment_pct": 40, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program", "summary": "Traws Pharma announced it is developing an updated toxicology data package for its influenza prophylaxis program, tivoxavir marboxil (TXM), in response to requirements from the UK's MHRA. This resubmission, expected in Q3 2026, aims to enable a Phase 2a human influenza Challenge ", "url": "https://www.globenewswire.com/news-release/2026/06/22/3315171/0/en/traws-pharma-provides-updated-guidance-on-influenza-prophylaxis-program.html", "source_name": "GlobeNewswire", "published_at": "2026-06-26T19:40:40", "published_display": "26 Jun 2026 19:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma, Inc. Actuals & Estimates (NASDAQ:TRAW)", "summary": "This article provides an overview of Traws Pharma, Inc. (NASDAQ:TRAW) financials and analyst estimates. Key information includes the current stock price, historical performance, analyst price targets, upcoming earnings dates, and financial metrics such as net income and EBITDA. T", "url": "https://www.tradingview.com/symbols/NASDAQ-TRAW/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T13:39:15", "published_display": "26 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "0T20 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a detailed forecast and financial overview for Traws Pharma, Inc. (0T20) on the Frankfurt Stock Exchange, based on analyst ratings and historical data. It includes information on price targets, past earnings, revenue, EBITDA, and key dates such as the next e", "url": "https://www.tradingview.com/symbols/FWB-0T20/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T23:39:15", "published_display": "25 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma Says Updated Toxicology Data Being Developed on Influenza Prophylaxis Program", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/traws-pharma-says-updated-toxicology-122355728.html", "source_name": "MT Newswires", "published_at": "2026-06-22T12:23:55+00:00", "published_display": "22 Jun 2026 12:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma Delays Phase 2 Influenza Study After UK Regulatory Review; Shares Down Pre-Bell", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/traws-pharma-delays-phase-2-104229416.html", "source_name": "MT Newswires", "published_at": "2026-06-15T10:42:29+00:00", "published_display": "15 Jun 2026 10:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma Shares Slide After UK Regulator Postpones Influenza Study", "summary": "", "url": "https://finance.yahoo.com/m/b775bfc6-294e-3246-9e8a-ee7892d2ef9b/traws-pharma-shares-slide.html", "source_name": "InvestorsHub", "published_at": "2026-06-15T10:26:33+00:00", "published_display": "15 Jun 2026 10:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma Provides Regulatory Update on Influenza Program", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/traws-pharma-provides-regulatory-influenza-213000779.html", "source_name": "GlobeNewswire", "published_at": "2026-06-12T21:30:00+00:00", "published_display": "12 Jun 2026 21:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regulator setback stalls Traws Pharma bird flu drug test in humans", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQV0F4OXZ6SWZKV29FOFRCb3VJLVgwN29lc3Q2QXVMNXduRFA2Nk5WOXU3TVVaaXVBTm13M3Qta0loTzNMVWtUcnNOTnNzN0YxN2lIdG9PcDFPLW01XzVSbFVxUXoyTE16dXRsMWh4aVZFbEhja1h4NW50LVBxbVA2RkszSk9jRFFIWllCMFpwT3RaQ2RWazNqRVhob25CcjVTeUZza3VlLUx5dzA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/traws-pharma-announces-antiviral-program-124500454.html", "source_name": "GlobeNewswire", "published_at": "2026-05-27T12:45:00+00:00", "published_display": "27 May 2026 12:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/traws-pharma-provides-business-highlights-110000040.html", "source_name": "GlobeNewswire", "published_at": "2026-05-15T11:00:00+00:00", "published_display": "15 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TRAW Stock Price and Chart \u2014 NASDAQ:TRAW", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE81NXdVSkRpeTdhd0pkZkZxa2xQa2MxN1JBMWN2X1I2a0xGa0xjbHZCajdDdXRVbUx3MHcwbVVBTmFyR2w5SjlOUFA5Mk8zbnphVnFLT3RqNFkxRGNf?oc=5", "source_name": "TradingView", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma Advances Development of Clinical Candidates for Hantavirus Treatment", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOeVVCMHdYSzZ0Vm5RbC0zSXNwckJ4QUJ5b1ZmQ0xmMy0ybmVHeGRNakNwSFE1T1ZzS2tsWXBtMHdZU2NpeUhvRWoxM05XWWtGVnZlVHNPQ0psU0N0RVJJUE82aHVWcmhNWjFFcE1xMEk0ckZtWmJiQk9wb0E3bFNyeEIwem9oeWNPNnlMdnp3M2RDM2ZrejRQU3hDRkdSeFh3cDVCa1NjTkFlTlFNWGd2OXlQRjE?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "No approved hantavirus treatment; Traws plans drug push", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQSGZyUnM5ZWI3YVFYNk1zOE1NdzBnRGVvNnY2ZTY1SUxtNjhWUDR3VlFNM0RRa1J3MEw2ZU5aNUJOdmVHbzN1eUV3V1g4QlJxa3F1SXNfaXZOazl4d3BIT3VYSWNXWGpkbk9LRDlHRndVZ2s3OGpRX2pTSENWc3I4TzRsRDZmTlUtcUxLazNheHV1Yk9tX3JtdHk2Z3VmTTNiMDg3OW5QMldJekE0Nm4yTFI4cVlpZHc?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma Stock (TRAW) Opinions on Insider Purchase", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPOW1UbXc4N2s2YTlmUXUzckNxRjhkbnpCWXVhWkIyanFGYXFNYlNjWkQ4V0dZZi1fMmI3TUpKTjlnQTY2b0FOYTNEbm9FXzJ6YUN1SnhXdVhHUEhGVTJmMEkxUjdUVS01VE5lU0hvTTNSWWRVRWpQSnBRcFR6Vnd4VTdObERSekotanZDTGFzTXJ3b0x0cHc?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma stock tumbles after FDA places tivoxavir marboxil on clinical hold", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxNeGhDaHlkNjY0ckZQbGd3ZktGWTIzSGxFUVRTanI4YjFiT016dFRGSHVQSUFua2R3UlJUXzhmMmZuTU1aTmZPdmNMS0NONFdZdzJMcHNkdTNIWjRIQWxSamRvMnJYZHBoSDlLY3ZldW1GRDdSRDM1ZUJXejdVamJMZXhleHlVbVF2aDE3cUFqdXVxYzFqMnZxcnBjVVJmeU1RR1BXeUtsb3hWZVhQTnFtamh0X1BIVGlibk1wVEFMc0NNckZYMDFMbnpiazhTVi1tNkhyTEI2bWE?oc=5", "source_name": "Investing.com", "published_at": "2026-02-19T08:00:00+00:00", "published_display": "19 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma Stock Hits 6-Month Highs On Bird Flu Treatment Breakthrough, Retail Interest Soars", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOQ0dtSzJrNEt0ckR0X2toOERNTnUxNmV4LXlvaWRieC1kM2ZUWlE0Y2lodGNzYkpzekhZODBCOHd2UExMWjFEbzFOMkVlWkFMcmpucGR0TkExblJzSGRTclJTUVJtQ0llZEhOenMtbFNQR3hVbTZuLTdGc0tqU2ZkR0F1OEF0aFctdWZsai1RVllaVS1uZWZTemc1N0swN0VaWGpJSnZEaTRxeGp5cW1sMjlR?oc=5", "source_name": "Stocktwits", "published_at": "2024-12-23T17:12:12+00:00", "published_display": "23 Dec 2024 17:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Traws Pharma (TRAW) Stock News & Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTE5TMDB0ZVpnMnBJQXNpd1lwYzRzQUJvbTY5OVR1WWpZOUd2UjMyTUFCSUpqXzdLclJNYlhZTTVid01pc29kbHc3OFJBa0VRdw?oc=5", "source_name": "Stock Titan", "published_at": "2024-05-07T19:03:12+00:00", "published_display": "07 May 2024 19:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 90, "total_relevant": 53, "sentiment_summary": {"positive": 4, "negative": 7, "neutral": 42, "score": 49, "total": 53, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 83, "events": [{"event": "general", "label": "Market update", "weight": 18.15, "count": 33}, {"event": "earnings", "label": "Earnings", "weight": 5.91, "count": 13}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.65, "count": 3}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 4, "negative_events": 7}, "market_context": {"has_market_context": true, "latest_close": 0.67, "latest_week": "2026-07-17", "one_week_move": -11.7, "four_week_move": -21.1, "twelve_week_move": -42.2, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.179444, "market_dynamics_buy_signal": false, "relative_strength": -65.782384, "fair_value_gap": -91.7, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 38.911, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-11.7% over one week, -21.1% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 60, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 18}, {"label": "TradingView", "count": 7}, {"label": "Market source", "count": 6}, {"label": "GlobeNewswire", "count": 4}, {"label": "Quartr", "count": 2}, {"label": "Investing.com Nigeria", "count": 2}, {"label": "MT Newswires", "count": 2}, {"label": "simplywall.st", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 44}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 33}, {"label": "Earnings", "count": 13}, {"label": "Regulatory and legal", "count": 3}, {"label": "Balance sheet", "count": 2}, {"label": "Analyst action", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "49/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "83/100 classification confidence."}, {"label": "Company focus", "value": "44", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-11.7% over one week, -21.1% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "Traws Pharma (TRAW) Registration filing Summary"}], "updated_at": "2026-07-22T09:11:56.957891+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}